美国NDC复合药物数据库文件

药品名称：商品名称：药品NDC：报告期内： -格式:2020-5-3
NDC包装id：市场分类：活性成分：持证企业：

美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)

药品名称(分析)

商品名

药品NDC

专利人(分析)

报告期内

活性成分

市场分类

规格(分析)

NDC包装id

Cyclopentaloate 2%, Phenyephrine 2.5%, Tropicamide 0.5%

HUMAN COMPOUNDED DRUG

26436-5526

Hybrid Pharma

2024-2

PHENYLEPHRINE HYDROCHLORIDE, (+/-)-; TROPICAMIDE; CYCLOPENTOLATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

25 mg/1 mL; 5 mg/1 mL; 5 mg/1 mL

26436-5526-0

Bimix 30/2

HUMAN COMPOUNDED DRUG

26436-5145

Hybrid Pharma

2024-2

PAPAVERINE HYDROCHLORIDE; PHENTOLAMINE MESYLATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

30 mg/1 mL; 2 mg/1 mL

26436-5145-5

Lidocaine, Epinephrine, Tetracaine

HUMAN COMPOUNDED DRUG

71266-6290

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

LIDOCAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE; TETRACAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

40 mg/1 mL; 1.8 mg/1 mL; 5 mg/1 mL

71266-6290-1

Fentanyl

HUMAN COMPOUNDED DRUG

71266-5010

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

FENTANYL CITRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

71266-5010-1

Fentanyl

HUMAN COMPOUNDED DRUG

71266-5040

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

FENTANYL CITRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

20 ug/1 mL

71266-5040-1

Fentanyl

HUMAN COMPOUNDED DRUG

71266-5005

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

FENTANYL CITRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

50 ug/1 mL

71266-5005-1

Hydromorphone HCl

HUMAN COMPOUNDED DRUG

71266-5035

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

HYDROMORPHONE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.2 mg/1 mL

71266-5035-1

Fentanyl

HUMAN COMPOUNDED DRUG

71266-5050

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

FENTANYL CITRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 ug/1 mL

71266-5050-1

Norepinephrine Bitartrate

HUMAN COMPOUNDED DRUG

71266-5015

Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories

2024-2

NOREPINEPHRINE BITARTRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

32 ug/1 mL

71266-5015-2

DEXAMETHASONE SODIUM PHOSPHATE AND LIDOCAINE HCL

HUMAN COMPOUNDED DRUG

71300-6555

Nubratori Inc.

2024-2

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

3.33 mg/1 mL; 6.67 mg/1 mL

71300-6555-1

031081 MINOXIDIL 7% / TRETINOIN 0.025% Solution

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.025 g/100 mL; 7 g/100 mL

72934-4351-8

351012 LIDOCAINE2%/MUPIROCIN2%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 g/100 mL; 2 g/100 mL

72934-5417-2

031016 BETAMETHASONE DIPROPIONATE 0.05% / MINOXIDIL 5% / NIACINAMIDE 2% / PENTOXIFYLLINE 0.5% Solution

HUMAN COMPOUNDED DRUG

72934-4344

SKNV

2024-2

BETAMETHASONE DIPROPIONATE; MINOXIDIL; NIACINAMIDE; PENTOXIFYLLINE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.05 g/100 mL; 5 g/100 mL; 2 g/100 mL; .5 g/100 mL

72934-4344-8

141067 HYDROQUINONE 8%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

8 g/100 mL

72934-6390-2

141011 HYDROQUINONE 6%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

6 g/100 mL

72934-6372-2

271036 NIACINAMIDE 4% / TRETINOIN 0.05%

HUMAN COMPOUNDED DRUG

72934-2429

SKNV

2024-2

NIACINAMIDE; TRETINOIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .05 g/100 mL

72934-2429-2

011009 NIACINAMIDE 4% / TRETINOIN 0.05%

HUMAN COMPOUNDED DRUG

72934-2299

SKNV

2024-2

NIACINAMIDE; TRETINOIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .05 g/100 mL

72934-2299-4

011020 NIACINAMIDE 4% / TRETINOIN 0.05%

HUMAN COMPOUNDED DRUG

72934-1304

SKNV

2024-2

NIACINAMIDE; TRETINOIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .05 g/100 mL

72934-1304-2

011013 NIACINAMIDE 4% / TRETINOIN 0.025%

HUMAN COMPOUNDED DRUG

72934-2300

SKNV

2024-2

NIACINAMIDE; TRETINOIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .025 g/100 mL

72934-2300-2

141025 HYDROCORTISONE 0.5% / HYDROQUINONE 8% / TRETINOIN 0.05%

HUMAN COMPOUNDED DRUG

72934-6378

SKNV

2024-1

HYDROCORTISONE; HYDROQUINONE; TRETINOIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.5 g/100 mL; 8 g/100 mL; .05 g/100 mL

72934-6378-2

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：